AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23521105 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal mask airway Unique (laryngeal mask airway-U) at 60 cm H(2)O
Number of subjects: 180
Study 23521105 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway Supreme (Supreme) at 40 cm H(2)O
Number of subjects: 180
Study 23521105 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal mask airway Unique (laryngeal mask airway-U) at 40 cm H(2)O
Number of subjects: 180
Study 23521105 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway Supreme (Supreme)
Number of subjects: 180
Study 23521105 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal mask airway Unique (laryngeal mask airway-U)
Number of subjects: 180
Study 21558397 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied CUR61414 (0.09%, 0.35%, 1.1%, and 3.1%) for up to 28 days
Number of subjects: 0
Study 21558397 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical CUR61414 in preclinical studies
Number of subjects: 0
Study 19465442 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone (500 microg twice daily from a Diskus inhaler)
Number of subjects: 41
Study 19465442 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone (30 mg daily)
Number of subjects: 41
Study 17525499 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic treatment
Number of subjects: 0
Study 17525499 — intervention group
Group type: COMPARATOR
Intervention: Initial and second-screening systems
Number of subjects: 0
Study 15202770 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute oral lorazepam (0.5 mg or 1 mg)
Number of subjects: 18
Study 15202770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 11423918 — intervention group
Group type: EXPERIMENTAL
Intervention: BIA (bioelectrical impedance analysis)
Number of subjects: 27
Study 11423918 — intervention group
Group type: EXPERIMENTAL
Intervention: DXA (dual energy X-ray absorptiometry)
Number of subjects: 27
Study 11423918 — intervention group
Group type: COMPARATOR
Intervention: BIA
Number of subjects: 27
Study 11423918 — intervention group
Group type: EXPERIMENTAL
Intervention: BIA and DXA
Number of subjects: 27
Study 9537307 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of bombesin (0.09 nmol/kg ideal weight/h)
Number of subjects: 14
Study 9537307 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (placebo)
Number of subjects: 14
Study 7625786 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 12
Study 7625786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7625786 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomefloxacin
Number of subjects: 12
Study 7625786 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 12
Study 2225536 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% hydrocortisone (DAK)
Number of subjects: 10
Study 2225536 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% triamcinolone acetonide (Kenalogue)
Number of subjects: 10
Study 2225536 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% betamethasone‐17‐valerate cream (Betnovate)
Number of subjects: 10
Study 2225536 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% clobetasol proprionate cream (Dermovate)
Number of subjects: 10
Study 2225536 — intervention group
Group type: COMPARATOR
Intervention: base cream
Number of subjects: 10
Study 213459 — intervention group
Group type: EXPERIMENTAL
Intervention: Day care
Number of subjects: 360
Study 213459 — intervention group
Group type: COMPARATOR
Intervention: Caring persons' reactions
Number of subjects: 360
Study 31686785 — intervention group
Group type: EXPERIMENTAL
Intervention: travoprost 0.004%
Number of subjects: 79
Study 31686785 — intervention group
Group type: COMPARATOR
Intervention: timolol 0.5%
Number of subjects: 79
Study 29122156 — intervention group
Group type: EXPERIMENTAL
Intervention: Reslizumab 3.0 mg/kg intravenously every 4 weeks for up to 24 months
Number of subjects: 1051
Study 25744962 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT) plus Healthy Lifestyles intervention
Number of subjects: 235
Study 25744962 — intervention group
Group type: COMPARATOR
Intervention: Nicotine Replacement Therapy (NRT) plus predominantly telephone-based intervention
Number of subjects: 235
Study 23512860 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI) on statin therapy
Number of subjects: 1431
Study 23512860 — intervention group
Group type: COMPARATOR
Intervention: Usual care on statin therapy
Number of subjects: 1431
Study 23512860 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI) not on statin therapy
Number of subjects: 1431
Study 21545068 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 37
Study 21545068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 19704175 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC278 25 mg
Number of subjects: 36
Study 19704175 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC278 50 mg
Number of subjects: 36
Study 19704175 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC278 150 mg
Number of subjects: 36
Study 19704175 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC278 (overall)
Number of subjects: 36
Study 16916429 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine ingestion before stress
Number of subjects: 47
Study 16916429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 13129464 — intervention group
Group type: EXPERIMENTAL
Intervention: FOS-supplemented infant cereal (0.75 g FOS per serving)
Number of subjects: 56
Study 13129464 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 56
Study 10574519 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency contracting
Number of subjects: 0
Study 10574519 — intervention group
Group type: COMPARATOR
Intervention: Free care
Number of subjects: 0
Study 10574519 — intervention group
Group type: EXPERIMENTAL
Intervention: Paid participation
Number of subjects: 0
Study 10574519 — intervention group
Group type: COMPARATOR
Intervention: Commercial weight loss program
Number of subjects: 0
Study 8912022 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Neural Net classifier
Number of subjects: 0
Study 8912022 — intervention group
Group type: COMPARATOR
Intervention: Bayesian classifier
Number of subjects: 0
Study 1987410 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder training
Number of subjects: 123
Study 6347749 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen (0.5-1 mg b.i.d. for 12 weeks)
Number of subjects: 50
Study 6347749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 2582325 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive cyclic therapy using either the same drugs of the induction regimen or rotating combinations of alternative drugs (e.g., mAMSA, 5-AZA, HD-Ara C)
Number of subjects: 266
Study 2582325 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance arm I
Number of subjects: 266
Study 2582325 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance arm II
Number of subjects: 266
Study 2582325 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction treatment
Number of subjects: 266
Study 2582325 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction or maintenance treatment
Number of subjects: 266
Study 2582325 — intervention group
Group type: EXPERIMENTAL
Intervention: Remission duration or survival
Number of subjects: 266
Study 29190004 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored dose-dense epirubicin and cyclophosphamide (EC) followed by docetaxel (T) (group A)
Number of subjects: 124
Study 29190004 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed doses of the same regimen (group B)
Number of subjects: 124
Study 29190004 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC regimen (group C)
Number of subjects: 124
Study 27392509 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Ventricular Mass
Number of subjects: 100
Study 24536058 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-to-use supplementary food (RUSF)
Number of subjects: 524
Study 24536058 — intervention group
Group type: COMPARATOR
Intervention: Corn-soy blend plus (CSB+)
Number of subjects: 524
Study 22849958 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-open muscle splitting incision (MSI)
Number of subjects: 50
Study 22849958 — intervention group
Group type: COMPARATOR
Intervention: Hand-assisted laparoscopic technique (HAL)
Number of subjects: 50
Study 20407435 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive tasks designed to improve reasoning, memory, planning, visuospatial skills, and attention, trained several times each week for six weeks.
Number of subjects: 11430
Study 18199863 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (0.8 mg/kg, max 50 mg)
Number of subjects: 211
Study 18199863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study 18199863 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (after 24 weeks of open-label treatment)
Number of subjects: 211
Study 18199863 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after 24 weeks of open-label treatment)
Number of subjects: 211
Study 18199863 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during withdrawal from week 36 to week 48)
Number of subjects: 211
Study 18199863 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (open-label treatment)
Number of subjects: 211
Study 15928526 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus a kit of nonpharmacologic strategies
Number of subjects: 65
Study 15928526 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 65
Study 12575908 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey preload (48 g, 1700 kJ liquid preload)
Number of subjects: 0
Study 12575908 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey test meal
Number of subjects: 0
Study 10232292 — intervention group
Group type: EXPERIMENTAL
Intervention: Active catecholamine depletion via oral administration of 5 g alpha‐methylparatyrosine
Number of subjects: 27
Study 10232292 — intervention group
Group type: COMPARATOR
Intervention: Sham catecholamine depletion via oral administration of 250 mg diphenhydramine hydrochloride
Number of subjects: 27
Study 8734351 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (1000 mg)
Number of subjects: 16
Study 8734351 — intervention group
Group type: COMPARATOR
Intervention: Water (placebo)
Number of subjects: 16
Study 1746734 — intervention group
Group type: EXPERIMENTAL
Intervention: Manikin-only training
Number of subjects: 0
Study 1746734 — intervention group
Group type: COMPARATOR
Intervention: Manikin-plus-cadaver training
Number of subjects: 0
Study 7105826 — intervention group
Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide/amiloride
Number of subjects: 70
Study 7105826 — intervention group
Group type: COMPARATOR
Intervention: cyclopenthiazide/potassium
Number of subjects: 70
Study 31575569 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring only (self-weighing and activity tracker)
Number of subjects: 1627
Study 31575569 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation and motivation
Number of subjects: 1627
Study 31575569 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion regulation
Number of subjects: 1627
Study 31575569 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined self-regulation, motivation and emotion regulation
Number of subjects: 1627
Study 31575569 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1627
Study 31575569 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 1627
Study 28834385 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep sclerectomy with mitomycin-C (MMC)
Number of subjects: 37
Study 28834385 — intervention group
Group type: COMPARATOR
Intervention: Deep sclerectomy without mitomycin-C (non-MMC)
Number of subjects: 37
Study 27112475 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial infusion with 8 ml of 1% methylene blue
Number of subjects: 112
Study 27112475 — intervention group
Group type: COMPARATOR
Intervention: Control group without artery infusion
Number of subjects: 112
Study 25530465 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrupted Force (IF)
Number of subjects: 30
Study 25530465 — intervention group
Group type: COMPARATOR
Intervention: Continuous Force (CF)
Number of subjects: 30
Study 22627477 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐04523655 (50 to 3000 μg)
Number of subjects: 54
Study 19067709 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-compound scalp formulation (calcipotriol 50 microg g(‐1) plus betamethasone 0.5 mg g(‐1))
Number of subjects: 1417
Study 19067709 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone dipropionate 0.5 mg g(‐1)
Number of subjects: 1417
Study 19067709 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriol 50 microg g(‐1)
Number of subjects: 1417
Study 17976797 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg tramadol ingested 1.5 h before oxycodone
Number of subjects: 10
Study 17976797 — intervention group
Group type: COMPARATOR
Intervention: 10 mg immediate-release oxycodone orally
Number of subjects: 10
Study 16356868 — intervention group
Group type: EXPERIMENTAL
Intervention: Aciclovir (ACV) plus recombinant interferon-beta (rIFN-beta)
Number of subjects: 59
Study 16356868 — intervention group
Group type: COMPARATOR
Intervention: Aciclovir (ACV) plus placebo
Number of subjects: 59
Study 12593694 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin 1 g intravenously before operation and 1 g intravenously at the end of cardiopulmonary bypass (Group 1)
Number of subjects: 137
Study 12593694 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin 2 g intravenously before operation, followed by continuous intravenous infusion at 20 mg/min throughout surgery (Group 2)
Number of subjects: 137
Study 12593694 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin 3 g intravenously before operation, followed by continuous intravenous infusion at 15 mg/min throughout surgery (Group 3)
Number of subjects: 137
Study 10491209 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D receptor genotype (TaqI, ApaI)
Number of subjects: 9704
Study 10491209 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D receptor polymorphisms (TaqI and ApaI)
Number of subjects: 9704
Study 8708714 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (250 mg three times daily)
Number of subjects: 92
Study 8708714 — intervention group
Group type: COMPARATOR
Intervention: Diethylstilbestrol (DES, 1 mg three times daily)
Number of subjects: 92
Study 8708714 — intervention group
Group type: COMPARATOR
Intervention: Diethylstilbestrol (DES)
Number of subjects: 92
Study 8708714 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide
Number of subjects: 92
Study 1678800 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 1113
Study 1678800 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant locoregional radiotherapy
Number of subjects: 1113
Study 1678800 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 1113
Study 6293321 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy regimen producing less depression and fatigue
Number of subjects: 77
Study 6293321 — intervention group
Group type: COMPARATOR
Intervention: Other chemotherapy regimen
Number of subjects: 77
Study 12185396 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 40 mg daily
Number of subjects: 0
Study 12185396 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 60 mg daily
Number of subjects: 0
Study 12185396 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 10 mg daily
Number of subjects: 0
Study 12185396 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 20 mg daily
Number of subjects: 0
Study 12185396 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 40 mg and 60 mg daily
Number of subjects: 0
Study 12185396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30652031 — intervention group
Group type: EXPERIMENTAL
Intervention: PPARG2 Pro12Ala Ala carriers
Number of subjects: 150
Study 30652031 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined genotypes ProAla + AlaAla and GC + CC
Number of subjects: 150
Study 30652031 — intervention group
Group type: EXPERIMENTAL
Intervention: PPARG2 Ala allele carriers (ProAla + AlaAla and GG)
Number of subjects: 150
Study 30652031 — intervention group
Group type: COMPARATOR
Intervention: IL6 ‐174G >C polymorphism
Number of subjects: 150
Study 27835716 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) treatment for 8 weeks
Number of subjects: 79
Study 27835716 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) treatment
Number of subjects: 79
Study 27835716 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) treatment for patients with objective memory dysfunction at baseline (n = 16)
Number of subjects: 79
Study 27835716 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) treatment
Number of subjects: 79
Study 24867313 — intervention group
Group type: EXPERIMENTAL
Intervention: ETDRS charts
Number of subjects: 75
Study 24867313 — intervention group
Group type: COMPARATOR
Intervention: Landolt C test
Number of subjects: 75
Study 21847713 — intervention group
Group type: COMPARATOR
Intervention: 0 g/day RPM
Number of subjects: 16
Study 21847713 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 g/day RPM
Number of subjects: 16
Study 21847713 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 g/day RPM
Number of subjects: 16
Study 21847713 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5 g/day RPM
Number of subjects: 16
Study 20303474 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg single oral dose of D-cycloserine (DCS)
Number of subjects: 40
Study 20303474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 18777201 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper-based EQ VAS (20 cm vertical)
Number of subjects: 314
Study 18777201 — intervention group
Group type: EXPERIMENTAL
Intervention: Touch-screen EQ VAS (horizontal)
Number of subjects: 314
Study 18777201 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both modes
Number of subjects: 314
Study 16189520 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary hrHPV screening
Number of subjects: 14149
Study 16189520 — intervention group
Group type: COMPARATOR
Intervention: Cytology triage
Number of subjects: 14149
Study 12235506 — intervention group
Group type: EXPERIMENTAL
Intervention: HERMES-assisted laparoscopic operations
Number of subjects: 30
Study 12235506 — intervention group
Group type: COMPARATOR
Intervention: Standard laparoscopic operations (non-HERMES)
Number of subjects: 30
Study 9698813 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 5 mg/kg
Number of subjects: 8
Study 9698813 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 8
Study 7894879 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride 100 mg/d
Number of subjects: 104
Study 7894879 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride 300 mg/d
Number of subjects: 104
Study 7894879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 2484467 — intervention group
Group type: EXPERIMENTAL
Intervention: MSD vaccine (2 doses)
Number of subjects: 0
Study 2484467 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasteur vaccine (3 doses)
Number of subjects: 0
Study 589786 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol Rotahaler
Number of subjects: 2
Study 589786 — intervention group
Group type: COMPARATOR
Intervention: Conventional pressurized aerosol
Number of subjects: 2
Study 31296255 — intervention group
Group type: EXPERIMENTAL
Intervention: ARK-Hospital intervention
Number of subjects: 36
Study 28477702 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training with virtual reality (RAGT+VR)
Number of subjects: 40
Study 28477702 — intervention group
Group type: COMPARATOR
Intervention: Robot-assisted gait training without virtual reality (RAGT)
Number of subjects: 40
Study 25486932 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication adherence information (AI) provided to physician
Number of subjects: 1692
Study 25486932 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication adherence information (AI) and motivational interviewing (MI)
Number of subjects: 1692
Study 25486932 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 1692
Study 23023528 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenretinide 300 mg daily
Number of subjects: 246
Study 23023528 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenretinide (combined groups)
Number of subjects: 246
Study 23023528 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenretinide 100 mg daily
Number of subjects: 246
Study 23023528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study 21612949 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive elastic compression stockings (PECS)
Number of subjects: 30
Study 21612949 — intervention group
Group type: COMPARATOR
Intervention: Graduated elastic compression stockings (GECS)
Number of subjects: 30
Study 19224107 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized cannabis extract containing Delta(9)-THC and cannabidiol
Number of subjects: 24
Study 19224107 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta(9)-THC
Number of subjects: 24
Study 19224107 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized cannabis extract
Number of subjects: 24
Study 16968803 — intervention group
Group type: EXPERIMENTAL
Intervention: Hook needle insertion under ultrasound guidance
Number of subjects: 10
Study 16968803 — intervention group
Group type: EXPERIMENTAL
Intervention: Hook needle insertion
Number of subjects: 10
Study 16968803 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical excision
Number of subjects: 10
Study 15710069 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day + UDCA 300 mg/day
Number of subjects: 48
Study 15710069 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 40 mg/day
Number of subjects: 48